KEROS THERAPEUTICS INC (KROS:NASDAQ)
$11.205 -1.285 (-10.2882%)
Analysed KEROS THERAPEUTICS INC (KROS:NASDAQ) News Sources
Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?
03-04-2026
yahoo.com
Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?
31-03-2026
yahoo.com
KROS: Is the Discount Book Value a Value Trap?
17-03-2026
yahoo.com
KROS Stock: What to Know About Rinvatercept in DMD
17-03-2026
yahoo.com
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
17-03-2026
yahoo.com
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
09-03-2026
yahoo.com
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
09-03-2026
yahoo.com
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?
06-03-2026
yahoo.com
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
04-03-2026
yahoo.com
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
04-03-2026
yahoo.com
What is the current price of KEROS THERAPEUTICS INC (KROS:NASDAQ)?
The current price of KEROS THERAPEUTICS INC (KROS:NASDAQ) is $11.205.
KEROS THERAPEUTICS INC (KROS:NASDAQ) absolute price change since previous trading day?
The absolute price change of KEROS THERAPEUTICS INC (KROS:NASDAQ) since the previous trading day is $-1.285.
KEROS THERAPEUTICS INC (KROS:NASDAQ) percentage price change since previous trading day?
The percentage price change of KEROS THERAPEUTICS INC (KROS:NASDAQ) since the previous trading day is -10.2882%.
What is the most recent average sentiment score for KEROS THERAPEUTICS INC (KROS:NASDAQ)?
The most recent average sentiment score for KEROS THERAPEUTICS INC (KROS:NASDAQ) is 70 out of 100.
What is the most recent average sentiment for KEROS THERAPEUTICS INC (KROS:NASDAQ)?
The most recent sentiment for KEROS THERAPEUTICS INC (KROS:NASDAQ) is .
SEC-8K** Filing Available For KEROS THERAPEUTICS INC (KROS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.